Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities

Abstract

HPD was observed in 7% of patients with solid tumors treated with immunotherapy. HPD was not associated with CSAEs, age, tumor type, or the type of immunotherapy but was more common in females.